ArriVent BioPharma, Inc. AVBP Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.1M+24.5% | $45.54M-38.7% | $112.67M-60.2% | $112.77M— | $49.87M— | ||
| $264.28M— | $267.28M— | $187.59M— | —— | —— | ||
| $348.7M+87.7% | $332.9M+46.7% | $321.22M+9.9% | $250.15M— | $185.79M— | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M— | $215.5M— | ||
| $8.73M+100.0% | $5.93M+56.9% | $5.93M+27.7% | $4.06M— | $4.36M— | ||
| $25M+93.0% | $25.95M+50.2% | $21.56M+42.2% | $19.64M— | $12.95M— | ||
| $25.32M+95.4% | $25.95M+50.1% | $21.56M+41.7% | $19.64M— | $12.95M— | ||
| $5K+25.0% | $4K+33.3% | $4K— | $4K— | $4K— | ||
| -$447.96M-48.0% | -$404.64M-69.8% | -$369.1M-69.5% | -$334.12M— | -$302.72M— | ||
| $323.98M+60.0% | $307.22M+19.2% | $305M+9.9% | $249.87M-15.8% | $202.54M-36.3% | ||
| $349.3M+62.1% | $333.17M+21.2% | $326.56M+11.6% | $269.51M— | $215.5M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can ArriVent BioPharma, Inc. cover its short-term obligations?
- Its current ratio is 13.95 — current assets exceed current liabilities.
- Where does ArriVent BioPharma, Inc.'s balance sheet data come from?
- Every line is extracted from ArriVent BioPharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.